CD86

Product List

Blew is our CD86 CAR related products. Please refer to the list provided to locate the products for your needs.

Background

Primarily expressed on antigen-presenting cells (APCs), cluster of differentiation 86 (CD86) plays an important role in the immune response. It is a promising target for CART therapy due to its selective expression on APCs, its role in T cell activation, and its potential to enhance the anti-tumor immune response.

Associated Diseases

• Acute myeloid leukemia (AML)
• Chronic lymphocytic leukemia (CLL)
• Melanoma
• Lung cancer

Anti-CD86 CAR-T Services

Anti-CD86 CAR-T In Vitro Assay Services

CD86 CAR-T Expression Test

We are pleased to provide anti-CD86 CAR expression analysis. Our comprehensive service aims to accurately evaluate the expression levels and functionality of anti-CD86 CAR in various research settings. The analysis includes the assessment of CAR surface expression on target cells, quantification of CAR expression using flow cytometry or other applicable methods.

CD86 CAR-T Cytokine Release Test

Our release test measures the level of cytokines released by CD86 CAR-T cells when they are activated, providing insights into their potential to cause cytokine release syndrome (CRS).

Fig.1 Secretion of IFNγ or IL-2.¹

CD86 CAR-T In Vitro Cytotoxicity Assay

Our highly skilled team of scientists and technicians is experienced in performing this assay using a variety of target cell lines and experimental conditions. We will tailor the assay design to meet your specific research needs and provide you with reliable and reproducible results. By availing of our CD86 CAR-T cell in vitro cytotoxicity assay service, you can accelerate your research and development efforts, saving time and resources. Our commitment to quality and scientific excellence ensures that you will receive reliable data to support your scientific objectives and make informed decisions.

Fig.2 Cytotoxicity analysis of CD86 CART and other CARTs.¹

CD86 CAR-T Cell Proliferation Test

Our team of highly skilled scientists and researchers work diligently to perform the CD86 CAR-T cell proliferation test with the utmost precision and attention to detail. Using state-of-the-art equipment and advanced methodologies, we measure the expansion and growth of CD86 CAR-T cells in response to specific stimuli or antigens.

Fig. 3 CD86 CART efficiently lysed all six AML cell lines.¹

Anti-CD86 CAR-T In Vivo Assay Services

CD86 CAR-T Cell Therapy Animal Models

Animal models provide you with an invaluable tool to evaluate the efficacy and safety of your CD86 CAR-T cell therapy candidates. Our models allow for the assessment of various parameters such as tumor regression, immune cell infiltration, cytokine production, and overall survival. We aim to accelerate the development of novel therapeutics and empower our clients to make informed decisions regarding CD86 CAR-T cell therapy candidates.

Fig.4 Anti-CD86 CART exhibited high potency in AML xenograft models.¹

Efficacy Test of CD86 CAR-T

Using cutting-edge technology and advanced imaging techniques, we provide detailed data on the therapeutic potential and anti-tumor activity of CD86 CAR-T cells. Our customers will gain valuable insights into the effectiveness of your therapy and make informed decisions regarding its development and future applications. Our team is committed to delivering high-quality data and timely results to support the advancement of CD86 CAR-T cell therapies in the fight against cancer.

Fig.5 CD86 CART can eliminate Mv4-11 tumor burden in vivo.¹

Toxicity Evaluation of CD86 CAR-T

We are pleased to offer the CD86 CAR-T cell toxicity evaluation service, which aims to assess the potential toxicity of CD86 CAR-T cell therapy. By performing these comprehensive evaluations, we will provide valuable data on the potential toxicity of CD86 CAR-T cell therapy.

contact us today and let us know how to assist you in your research and development endeavors.

Reference

1. Gottschlich, Adrian.; et al. "Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia." Nature Biotechnology (2023): 1-15.